Duration of dual anti-platelet therapy - State of the art after the DAPT and PEGASUS-TIMI 54 trials.

Abstract

Dual anti-platelet therapy is prescribed in the setting of coronary heart disease for the prevention of stent thrombosis and acute thrombotic events. The optimal duration of dual anti-platelet therapy is still under debate as numerous trials have shown non-inferiority of a strategy of early cessation of one of the agents as compared to the standard practice whereas two larger trials have demonstrated benefit of prolonging dual anti-platelet therapy.

• Authors: Charles Pirlet, Victor Legrand, Astrid Nyssen, Luc Pierard, Olivier Gach
• Journal: Acta cardiologica (Acta Cardiol) Vol. 72 Issue 3 Pg. 256-264 (Jun 2017) ISSN: 0001-5385 [Print] England
• PMID: 28636514 (Publication Type: Journal Article, Review)

Chemical References

• Platelet Aggregation Inhibitors

Topics

• Coronary Restenosis (prevention & control)
• Drug Therapy, Combination
• Humans
• Platelet Aggregation Inhibitors (therapeutic use)
• Prosthesis Failure
• Randomized Controlled Trials as Topic
• Stents (adverse effects)
• Thrombolytic Therapy (methods)
• Treatment Outcome